Wedbush Equities Analysts Lift Earnings Estimates for ORIC

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) – Equities researchers at Wedbush lifted their Q1 2025 earnings estimates for ORIC Pharmaceuticals in a note issued to investors on Tuesday, February 25th. Wedbush analyst D. Nierengarten now anticipates that the company will earn ($0.50) per share for the quarter, up from their previous estimate of ($0.52). Wedbush currently has a “Outperform” rating and a $20.00 target price on the stock. The consensus estimate for ORIC Pharmaceuticals’ current full-year earnings is ($2.17) per share. Wedbush also issued estimates for ORIC Pharmaceuticals’ Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.48) EPS, FY2025 earnings at ($1.95) EPS, FY2026 earnings at ($1.81) EPS and FY2027 earnings at ($1.95) EPS.

A number of other research firms have also recently commented on ORIC. Cantor Fitzgerald restated an “overweight” rating on shares of ORIC Pharmaceuticals in a report on Tuesday, January 14th. Guggenheim restated a “buy” rating on shares of ORIC Pharmaceuticals in a report on Wednesday. HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of ORIC Pharmaceuticals in a report on Friday, February 21st. Finally, JPMorgan Chase & Co. increased their target price on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an “overweight” rating in a report on Wednesday. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, ORIC Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $18.86.

ORIC Pharmaceuticals Trading Up 2.4 %

NASDAQ ORIC opened at $8.03 on Friday. The company’s 50-day moving average price is $9.27 and its 200-day moving average price is $9.47. The stock has a market cap of $570.35 million, a PE ratio of -4.41 and a beta of 1.20. ORIC Pharmaceuticals has a 12 month low of $6.33 and a 12 month high of $16.65.

ORIC Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings results on Tuesday, February 18th. The company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.01.

Insider Buying and Selling at ORIC Pharmaceuticals

In related news, CFO Dominic Piscitelli sold 8,851 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $8.28, for a total value of $73,286.28. Following the completion of the transaction, the chief financial officer now directly owns 106,764 shares of the company’s stock, valued at $884,005.92. This trade represents a 7.66 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Pratik S. Multani sold 8,850 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $8.28, for a total transaction of $73,278.00. Following the completion of the transaction, the insider now directly owns 46,765 shares of the company’s stock, valued at $387,214.20. The trade was a 15.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 42,361 shares of company stock valued at $350,749. 5.55% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ORIC Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ORIC. Boxer Capital Management LLC purchased a new position in ORIC Pharmaceuticals during the 4th quarter worth approximately $13,982,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of ORIC Pharmaceuticals during the 4th quarter worth approximately $5,845,000. Balyasny Asset Management L.P. grew its stake in shares of ORIC Pharmaceuticals by 37.5% during the 4th quarter. Balyasny Asset Management L.P. now owns 1,555,260 shares of the company’s stock worth $12,551,000 after purchasing an additional 424,194 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of ORIC Pharmaceuticals by 152.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 410,229 shares of the company’s stock worth $4,205,000 after purchasing an additional 247,863 shares during the period. Finally, Diadema Partners LP acquired a new stake in shares of ORIC Pharmaceuticals during the 4th quarter worth approximately $1,729,000. 95.05% of the stock is owned by hedge funds and other institutional investors.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.